Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Publikationen
Suchbegriffe: MULTIPLE SCLEROSIS - DRUG THERAPY , . Treffer: 24
2020
Auer, M; Bsteh, G; Hegen, H; Wurth, S; Zinganell, A; Berger, T; Deisenhammer, F; Pauli, FD
Late-onset neutropenia in a multiple sclerosis patient after first dose ocrelizumab switched from rituximab.
Mult Scler Relat Disord. 2020; 43(8):102155-102155
Doi: 10.1016/j.msard.2020.102155
Web of Science
PubMed
FullText
FullText_MUG
2017
Enzinger, C
High-frequency MRI monitoring should be performed in natalizumab-treated MS patients with higher risk of PML - NO.
Mult Scler. 2017; 23(6):767-770
Doi: 10.1177/1352458516681505
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
Robier, C; Amouzadeh-Ghadikolai, O; Bregant, C; Diez, J; Melinz, K; Quehenberger, F; Quasthoff, S
The frequency of occurrence of atypical lymphocytes in peripheral blood smears of natalizumab-treated patients with multiple sclerosis.
Int J Lab Hematol. 2017; 39(5):469-474
Doi: 10.1111/ijlh.12662
Web of Science
PubMed
FullText
FullText_MUG
Zeitelhofer, M; Adzemovic, MZ; Gomez-Cabrero, D; Bergman, P; Hochmeister, S; N'diaye, M; Paulson, A; Ruhrmann, S; Almgren, M; Tegnér, JN; Ekström, TJ; Guerreiro-Cacais, AO; Jagodic, M
Functional genomics analysis of vitamin D effects on CD4+ T cells in vivo in experimental autoimmune encephalomyelitis .
Proc Natl Acad Sci U S A. 2017; 114(9):E1678-E1687
Doi: 10.1073/pnas.1615783114
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
2015
Wattjes, MP; Rovira, À; Miller, D; Yousry, TA; Sormani, MP; de Stefano, MP; Tintoré, M; Auger, C; Tur, C; Filippi, M; Rocca, MA; Fazekas, F; Kappos, L; Polman, C; Frederik Barkhof, C; Xavier Montalban, C; MAGNIMS study group
Evidence-based guidelines: MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis--establishing disease prognosis and monitoring patients.
Nat Rev Neurol. 2015; 11(10):597-606
Doi: 10.1038/nrneurol.2015.157
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
2014
Robier, C; Amouzadeh-Ghadikolai, O; Bregant, C; Diez, J; Melinz, K; Neubauer, M; Quasthoff, S
The anti-VLA-4 antibody natalizumab induces erythroblastaemia in the majority of the treated patients with multiple sclerosis.
Mult Scler. 2014; 20(9):1269-1272
Doi: 10.1177/1352458514521307
Web of Science
PubMed
FullText
FullText_MUG
2013
Adzemovic, MZ; Zeitelhofer, M; Hochmeister, S; Gustafsson, SA; Jagodic, M
Efficacy of vitamin D in treating multiple sclerosis-like neuroinflammation depends on developmental stage.
Exp Neurol. 2013; 249(12):39-48
Doi: 10.1016/j.expneurol.2013.08.002
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
Klicek, R; Kolenc, D; Suran, J; Drmic, D; Brcic, L; Aralica, G; Sever, M; Holjevac, J; Radic, B; Turudic, T; Kokot, A; Patrlj, L; Rucman, R; Seiwerth, S; Sikiric, P
Stable gastric pentadecapeptide BPC 157 heals cysteamine-colitis and colon-colon-anastomosis and counteracts cuprizone brain injuries and motor disability.
J Physiol Pharmacol. 2013; 64(5): 597-612.
[OPEN ACCESS]
Web of Science
PubMed
Pilz, G; Harrer, A; Wipfler, P; Oppermann, K; Sellner, J; Fazekas, F; Trinka, E; Kraus, J
Tumefactive MS lesions under fingolimod: a case report and literature review.
Neurology. 2013; 81(19):1654-1658
Doi: 10.1212/01.wnl.0000435293.34351.11
(- Case Report)
Web of Science
PubMed
FullText
FullText_MUG
Preiningerova, JL; Baumhackl, U; Csepany, T; Czaplinski, A; Deisenhammer, F; Derfuss, T; Fabjan, TH; Fazekas, F; Fuchs, S; Havrdova, E; Ledinek, AH; Illes, Z; Jazbec, SS; Klimova, E; Komoly, S; Kurca, E; Linnebank, M; Lisy, L; Mares, J; Prochazkova, L; Csilla, R; Szilasiova, J; Stourac, P; Talab, R; Turcani, P; Vachova, M; Vecsei, L; Vodusek, D; Zapletalova, O; Berger, T
Recommendations for the use of prolonged-release fampridine in patients with multiple sclerosis (MS).
CNS Neurosci Ther. 2013; 19(5):302-306
Doi: 10.1111/cns.12101
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
Svenningsson, A; Falk, E; Celius, EG; Fuchs, S; Schreiber, K; Berkö, S; Sun, J; Penner, IK; Tynergy Trial Investigators
Natalizumab treatment reduces fatigue in multiple sclerosis. Results from the TYNERGY trial; a study in the real life setting.
PLoS One. 2013; 8(3):e58643-e58643
Doi: 10.1371/journal.pone.0058643
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
2011
Koller, S; Kränke, B
Nicolau syndrome following subcutaneous glatiramer-acetate injection.
J Am Acad Dermatol. 2011; 64(2): e16-e17.
Doi: 10.1016/j.jaad.2010.09.003
PubMed
FullText
FullText_MUG
2010
Fazekas, F
Where to go next with neuroprotection in multiple sclerosis?
Lancet Neurol. 2010; 9(7):647-648
Doi: 10.1016/S1474-4422(10)70133-2
Web of Science
PubMed
FullText
FullText_MUG
van den Elskamp, IJ; Boden, B; Dattola, V; Knol, DL; Filippi, M; Kappos, L; Fazekas, F; Wagner, K; Pohl, C; Sandbrink, R; Polman, CH; Uitdehaag, BMJ; Barkhof, F
Cerebral atrophy as outcome measure in short-term phase 2 clinical trials in multiple sclerosis.
Neuroradiology. 2010; 52(10):875-881
Doi: 10.1007/s00234-009-0645-1
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
Google Scholar
2006
Mix, E; Ibrahim, SM; Pahnke, J; Glass, A; Mazón-Peláez, I; Lemcke, S; Koczan, D; Gimsa, U; Bansemer, S; Scheel, T; Karopka, T; Böttcher, T; Müller, J; Dazert, E; Antipova, V; Hoffrogge, R; Wree, A; Zschiesche, M; Strauss, U; Kundt, G; Warzok, R; Gierl, L; Rolfs, A
3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitor Atorvastatin mediated effects depend on the activation status of target cells in PLP-EAE.
J Autoimmun. 2006; 27(4): 251-265.
Doi: 10.1016/j.jaut.2006.09.006
Web of Science
PubMed
FullText
FullText_MUG
2005
Fazekas, F
MS Management in Complex Cases: report from the MS Forum satellite symposium at the 20th ECTRIMS Congress, 6 October 2004, Vienna, Austria.
Int MS J. 2005; 12(1): 32-32.
(- Case Report)
PubMed
Fazekas, F; Sørensen, PS; Filippi, M; Ropele, S; Lin, X; Koelmel, HW; Fernandez, O; Pozzilli, C; O'Connor, P; Enriquez, MM; Hommes, OR; ESIMS
MRI results from the European Study on Intravenous Immunoglobulin in Secondary Progressive Multiple Sclerosis (ESIMS).
Mult Scler. 2005; 11(4):433-440
Doi: 10.1191/1352458505ms1196oa
Web of Science
PubMed
FullText
FullText_MUG
Google Scholar
Neuhaus, O; Stüve, O; Archelos, JJ; Hartung, HP
Putative mechanisms of action of statins in multiple sclerosis--comparison to interferon-beta and glatiramer acetate.
J NEUROL SCI 2005 233: 173-177.
Doi: 10.1016/j.jns.2005.03.030
Web of Science
PubMed
FullText
FullText_MUG
Google Scholar
2004
Gneiss, C; Reindl, M; Lutterotti, A; Ehling, R; Egg, R; Khalil, M; Berger, T; Deisenhammer, F
Interferon-beta: the neutralizing antibody (NAb) titre predicts reversion to NAb negativity.
Mult Scler. 2004; 10(5):507-510
Doi: 10.1191/1352458504ms1074oa
Web of Science
PubMed
FullText
FullText_MUG
2003
Neuhaus, O; Archelos, JJ; Hartung, HP
Immunomodulation in multiple sclerosis: from immunosuppression to neuroprotection.
Trends Pharmacol Sci. 2003; 24(3):131-138
Doi: 10.1016%2FS0165-6147%2803%2900028-2
Web of Science
PubMed
FullText
FullText_MUG
Google Scholar
Spindler, M; Weilbach, F; Beer, M; Sandstede, J; Kostler, H; Strotmann, J; Voelker, WF; Hahn, D; Ertl, G; Gold, RF
Non-invasive functional and biochemical assessment of mitoxantrone cardiotoxicity in patients with multiple sclerosis
J Cardiovasc Pharmacol. 2003; 42(5):680-687
Doi: 10.1097/00005344-200311000-00015
Web of Science
PubMed
FullText
FullText_MUG
Google Scholar
2002
Tan, IL; van Schijndel, RA; Fazekas, F; Filippi, M; Freitag, P; Miller, DH; Yousry, TA; Pouwels, PJ; Adèr, HJ; Barkhof, F
Image registration and subtraction to detect active T(2) lesions in MS: an interobserver study.
J Neurol. 2002; 249(6):767-773
Doi: 10.1007/s00415-002-0712-6
Web of Science
PubMed
FullText
FullText_MUG
2001
Hartung, HP
Current status of interferon beta-1b in multiple sclerosis therapy
Med Klin (Munich). 2001; 96 Suppl 1(5):11-16
Web of Science
PubMed
FullText
2000
Hartung, HP
NICE and drugs for multiple sclerosis. National Institute of Clinical Excellence.
Lancet. 2000; 356(9235):1114-1114
Doi: 10.1016/S0140-6736(05)74558-X
Web of Science
PubMed
FullText
FullText_MUG